| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Neil E Kay | Q54295335 |
| Clive S Zent | Q57078355 | ||
| P2860 | cites work | Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines | Q24616084 |
| Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia | Q24681296 | ||
| TP53 mutation and survival in chronic lymphocytic leukemia | Q27851577 | ||
| Cancer statistics, 2010 | Q27860525 | ||
| Genomic aberrations and survival in chronic lymphocytic leukemia | Q28141442 | ||
| Clinical staging of chronic lymphocytic leukemia | Q33337604 | ||
| Autoimmune cytopenia does not predict poor prognosis in chronic lymphocytic leukemia/small lymphocytic lymphoma | Q33349757 | ||
| The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma | Q33379107 | ||
| Treatment of autoimmune cytopenia complicating progressive chronic lymphocytic leukemia/small lymphocytic lymphoma with rituximab, cyclophosphamide, vincristine, and prednisone | Q33388795 | ||
| Autoimmune cytopenia in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance | Q33391574 | ||
| Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab | Q33770207 | ||
| Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia | Q33873337 | ||
| Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. | Q33873343 | ||
| Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia | Q34056768 | ||
| Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial | Q34141305 | ||
| CD5-positive chronic B-cell lymphoproliferative disorders: diagnosis and prognosis of a heterogeneous disease entity. | Q34143223 | ||
| A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis | Q34282319 | ||
| Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia | Q34402999 | ||
| Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia | Q34617307 | ||
| CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential | Q35769292 | ||
| Update on risk-stratified management for chronic lymphocytic leukemia | Q36634599 | ||
| Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug | Q36712736 | ||
| Skin lesions in chronic lymphocytic leukemia | Q36814959 | ||
| Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia | Q36843780 | ||
| De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience | Q37028638 | ||
| Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia | Q37059754 | ||
| Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning | Q37119402 | ||
| Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma | Q37163867 | ||
| Treatment of elderly patients with chronic lymphocytic leukemia | Q37386705 | ||
| Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia | Q37621400 | ||
| Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approaches | Q37771673 | ||
| Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial | Q42994283 | ||
| Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics | Q43200452 | ||
| Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia | Q43598918 | ||
| Veterans with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) have a markedly increased rate of second malignancy, which is the most common cause of death | Q44560759 | ||
| High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities | Q44613408 | ||
| Comorbidity and functional status are independent in older cancer patients | Q44747457 | ||
| Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features. | Q45104774 | ||
| CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma | Q45115068 | ||
| ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia | Q46112511 | ||
| ZAP-70 is expressed by a subset of normal human B-lymphocytes displaying an activated phenotype | Q46412983 | ||
| Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features | Q46860354 | ||
| Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. | Q46925495 | ||
| Allogeneic CD3/CD28 cross-linked Th1 memory cells provide potent adjuvant effects for active immunotherapy of leukemia/lymphoma. | Q51961547 | ||
| Detection of Richter's transformation of chronic lymphocytic leukemia by PET/CT. | Q53343426 | ||
| Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. | Q53596463 | ||
| A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. | Q53650474 | ||
| Interphase fluorescence in situ hybridization with an IGH probe is important in the evaluation of patients with a clinical diagnosis of chronic lymphocytic leukaemia. | Q53668927 | ||
| Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. | Q53962600 | ||
| Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vlambda2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope. | Q54789536 | ||
| ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. | Q55036524 | ||
| High incidence of chronic lymphocytic leukemia (CLL) diagnosed by immunophenotyping: A population-based Canadian cohort | Q58436738 | ||
| Karyotypic evolution in CLL: identification of a new sub-group of patients with deletions of 11q and advanced or progressive disease | Q71020959 | ||
| p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias | Q72626720 | ||
| 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis | Q73260738 | ||
| Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia | Q73267761 | ||
| Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists' Collaborative Group | Q77788775 | ||
| Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies | Q78773743 | ||
| Predictive value of blood and bone marrow flow cytometry in B-cell lymphoma classification: comparative analysis of flow cytometry and tissue biopsy in 252 patients | Q81610592 | ||
| A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease | Q82081716 | ||
| microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia | Q82589392 | ||
| Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects | Q83888306 | ||
| CD5+ B-cell lymphoproliferative disorders: Beyond chronic lymphocytic leukemia and mantle cell lymphoma | Q83981795 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | leukemia | Q29496 |
| lymphocyte | Q715347 | ||
| chronic lymphocytic leukemia | Q1088156 | ||
| P304 | page(s) | 1425-1434 | |
| P577 | publication date | 2011-06-08 | |
| P1433 | published in | Leukemia & Lymphoma | Q6534493 |
| P1476 | title | Management of patients with chronic lymphocytic leukemia with a high risk of adverse outcome: the Mayo Clinic approach | |
| P478 | volume | 52 |
| Q35569491 | Addition of granulocyte macrophage colony stimulating factor does not improve response to early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab |
| Q45792752 | An unusual presentation of a chronic lymphocytic leukemia patient with 17p deletion after reduced-intensity transplantation: Richter syndrome and concomitant graft-versus-host disease--case report. |
| Q39165643 | Attenuating homologous recombination stimulates an AID-induced antileukemic effect |
| Q36609259 | Chronic lymphocytic leukemia: inception to cure: are we there? |
| Q90143630 | Cognitive function in patients with chronic lymphocytic leukemia: a cross-sectional study examining effects of disease and treatment |
| Q38296806 | Fetuin-A levels and free leptin index are reduced in patients with chronic lymphocytic leukemia: a hospital-based case-control study |
| Q47359917 | Front-line treatment of patients with chronic lymphocytic leukemia: a systematic review and network meta-analysis |
| Q38003163 | High-risk clonal evolution in chronic B-lymphocytic leukemia: single-center interphase fluorescence in situ hybridization study and review of the literature |
| Q36222910 | Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia |
Search more.